MedPath
Found 396 clinical trials|View Analysis
Sort by:

Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

Phase 2
Not yet recruiting
Conditions
Squamous Non-Small Cell Lung Cancer SqNSCLC
Interventions
Drug: Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin
First Posted Date
2024-12-24
Last Posted Date
2024-12-27
Lead Sponsor
Jian-Guo Zhou, MD, PhD
Target Recruit Count
32
Registration Number
NCT06747169

A Study to Investigate ALE.P02 As Monotherapy in Adult Patients with Selected CLDN1+ Solid Tumors

Phase 1
Recruiting
Conditions
Squamous Non-small-cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Cervical Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Interventions
Drug: ALE.P02
First Posted Date
2024-12-24
Last Posted Date
2024-12-24
Lead Sponsor
Alentis Therapeutics AG
Target Recruit Count
170
Registration Number
NCT06747585
Locations
🇺🇸

NEXT Oncology Virginia, Fairfax, Virginia, United States

🇸🇬

National Cancer Centre Singapore, Singapore, South West, Singapore

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Phase 3
Recruiting
Conditions
Locally Advanced or Metastatic Non-squamous NSCLC
Harboring EGFR Sensitive Mutations NSCLC
Previously Untreated Systematically NSCLC
Interventions
Drug: JMT101
Drug: Osimertinib
First Posted Date
2024-12-16
Last Posted Date
2024-12-16
Lead Sponsor
Shanghai JMT-Bio Inc.
Target Recruit Count
516
Registration Number
NCT06735391
Locations
🇨🇳

Sun Yat sen University Cancer Prevention and Treatment Center, Guangzhou, China

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Phase 2
Not yet recruiting
Conditions
Recurrent Platinum-resistant Epithelial Ovarian Cancer
Triple Negative Breast Cancer (TNBC)
Cervical Cancers
Small Cell Lung Cancer
Hepatocellular Carcinoma (HCC)
Colorectal Cancer
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Drug: B1962
First Posted Date
2024-12-09
Last Posted Date
2024-12-09
Lead Sponsor
Tasly Biopharmaceuticals Co., Ltd.
Target Recruit Count
120
Registration Number
NCT06724263
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

A Study of SKB264 in Combination with Pembrolizumab Versus Chemotherapy in Combination with Pembrolizumab As First-Line Treatment for PD-L1 Negative Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2024-12-02
Last Posted Date
2024-12-02
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
432
Registration Number
NCT06711900
Locations
🇨🇳

Shanghai Oriental Hospital, Shanghai, China

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3
Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2024-11-18
Last Posted Date
2024-12-11
Lead Sponsor
AstraZeneca
Target Recruit Count
880
Registration Number
NCT06692738
Locations
🇻🇳

Research Site, Vinh, Vietnam

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Phase 3
Not yet recruiting
Conditions
Non Squamous Non Small Cell Lung Cancer
Interventions
First Posted Date
2024-11-13
Last Posted Date
2024-11-13
Lead Sponsor
mAbxience Research S.L.
Target Recruit Count
726
Registration Number
NCT06687369

A Study of SKB264 in Combination with Osimertinib Versus Osimertinib in Patients with Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3
Not yet recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: SKB264
Drug: Osimertinib
First Posted Date
2024-11-01
Last Posted Date
2024-11-01
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
420
Registration Number
NCT06670196
Locations
🇨🇳

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma

Conditions
Squamous Cell Lung Cancer
First Posted Date
2024-10-18
Last Posted Date
2024-12-12
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
1000
Registration Number
NCT06647836
Locations
🇨🇳

Union Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, Hubei, China

Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda As Add-on to Chemotherapy in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3
Recruiting
Conditions
Non Small Cell Lung Cancer
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Biological: FYB206
Biological: Keytruda
First Posted Date
2024-10-16
Last Posted Date
2024-12-13
Lead Sponsor
Formycon AG
Target Recruit Count
524
Registration Number
NCT06643117
Locations
🇲🇾

Formycon Investigative Site, Kuching, Malaysia

© Copyright 2025. All Rights Reserved by MedPath